Journal article icon

Journal article

Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature

Abstract:
Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid leukemia (AML), but its rational utilization is compromised by the fact that neither the determinants of clinical response nor its mechanism of action are defined. Co-administration of histone deacetylase inhibitors, such as vorinostat (VOR), is reported to improve the clinical activity of AZA, but this has not been prospectively studied in patients with AML. Experimental De... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1158/1078-0432.ccr-17-1423

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
RDM; Weatherall Institute of Molecular Medicine
Role:
Author
Expand authors...
More from this funder
Funding agency for:
Quek, L
Grant:
Biomedical Research Centre Funding scheme
More from this funder
Funding agency for:
Quek, L
Grant:
Biomedical Research Centre Funding scheme
More from this funder
Funding agency for:
Metzner, M
Grant:
Biomedical Research Centre Funding scheme
More from this funder
Funding agency for:
Metzner, M
Grant:
Biomedical Research Centre Funding scheme
More from this funder
Funding agency for:
Kennedy, A
Grant:
Biomedical Research Centre Funding scheme
Expand funders...
Publisher:
American Association for Cancer Research Publisher's website
Journal:
Clinical Cancer Research Journal website
Volume:
23
Issue:
21
Pages:
6430-6440
Publication date:
2017-08-01
Acceptance date:
2017-07-26
DOI:
EISSN:
1557-3265
ISSN:
1078-0432
Pmid:
28765326
Source identifiers:
710779

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP